Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 9/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boric Acid SCHEMBL29148170 | 0.93 | CHRM2 (0.51) | CHRM2CHRM1CHRM3HTR1BCNR1 | |
| SCHEMBL3797578 | 0.89 | CHRM2 (0.58) | CHRM2CHRM1CHRM3HTR1BCA1 | |
| SCHEMBL3792011 | 0.85 | HTR1B (0.55) | CHRM2CHRM1CHRM3HTR1BCNR1 | |
| SCHEMBL3800036 | 0.84 | HTR1B (0.58) | CHRM2CHRM1CHRM3HTR1BKDM4E | |
| SCHEMBL10245596 | 0.81 | HTR1B (0.59) | CHRM2CHRM1CHRM3HTR1BKDM4E | |
| SCHEMBL14756115 | 0.81 | CHRM2 (0.53) | CHRM2CHRM1CHRM3HTR1BKDM4E | |
| SCHEMBL31061981 | 0.81 | CHRM2 (0.53) | CHRM2CHRM1CHRM3HTR1BKDM4E | |
| SCHEMBL13230585 | 0.80 | HTR1B (0.58) | CHRM2CHRM1CHRM3HTR1BKDM4E | |
| SCHEMBL11985011 | 0.80 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HTR1BKDM4E | |
| SCHEMBL2095530 | 0.79 | HTR1B (0.53) | CHRM2CHRM1CHRM3HTR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354607-B | Negative liquid crystal compound, liquid crystal composition, liquid crystal display element and liquid crystal display | 石家庄诚志永华显示材料有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023107653-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-113354607-A | Negative liquid crystal compound, liquid crystal composition, liquid crystal display element and liquid crystal display | 石家庄诚志永华显示材料有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9163017-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8546405-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-10-01 | — | — | US | disclosed |
| US-8541424-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-7645400-B2 | Composition containing carbon nanotubes having a coating | MITSUBISHI RAYON CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090321688-A1 | Carbon Nanotube Composition, Composite Having a Coated Film Composed of the Same, and Their Production Methods | MITSUBISHI RAYON CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4792/4885 |
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4792/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | CHRM2 640/4885CHRM1 714/4885CHRM3 338/4885 |
| US-20140213601-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4792/4885 |
| US-20120208806-A1 | Hsp90 Inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | CHRM2 4883/4885CHRM1 4884/4885CHRM3 4880/4885 |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | XDH, HSP90B1, HSP90AA1 | CHRM2 4527/4885CHRM1 4238/4885CHRM3 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.